Key result
Aliskiren demonstrated antifibrotic potential across several experimental models by attenuating remodeling, collagen deposition, and oxidative stress in multiple organs.
Why the study?
High levels of circulating renin and prorenin activate pathological fibrosis pathways, motivating an analysis of experimental studies evaluating the antifibrotic actions of the direct renin inhibitor aliskiren.
Does aliskiren reduce fibrosis in experimental models?
Population
Fifty-three experimental studies on aliskiren and fibrosis
Design
Systematic review
Authors
Loading...
Aliskiren merits human trials for fibrotic diseases; extends renin inhibition data to multiple organ models.
Systematic Review (n=53)
Does aliskiren reduce fibrosis in experimental models?
Aliskiren demonstrates antifibrotic potential across multiple organs in experimental models by interfering with fibrogenic cytokines and oxidative stress.
Marin et al. (2019) conducted a systematic review in Fibrosis (experimental models) (n=53). Aliskiren was evaluated on Fibrosis and related pathological changes. Aliskiren demonstrated antifibrotic potential across several experimental models by attenuating remodeling, collagen deposition, and oxidative stress in multiple organs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: